Jeffrey L. Boyd

Family management in the prevention of exacerbations of schizophrenia: a controlled study.

Environmental stress has been implicated as an important factor in the relapse of schizophrenic patients receiving optimal drug therapy. In a randomized controlled study, we compared at-home family therapy with clinic-based individual supportive care in the community management of schizophrenia in 36 patients taking neuroleptic maintenance medications. The family-treatment approach sought to enhance the stress-reducing capacity of the patient and his or her family through improved understanding of the illness and training in behavioral methods of problem solving. The results at the end of nine months revealed the superiority of this approach in preventing major symptomatic exacerbations. Only one family-treated patient (6 per cent of all patients) was judged to have had a clinical relapse, as compared with eight patients (44 per cent) treated individually. Family-treated patients averaged 0.83 days in the hospital, as compared with 8.39 days for the comparison group. Significantly lower levels of schizophrenic symptomatology on blind rating-scale assessments supported these clinical observations of the superiority of family management.

Family management in the prevention of morbidity of schizophrenia: social outcome of a two-year longitudinal study

Effective community treatment of schizophrenia involves not merely the removal of florid symptoms, but restoration of effective social role functioning. The efficacy of a family management approach is compared with an individual approach of similar intensity in terms of its impact on the patients social adjustment after a florid episode of schizophrenia. Clinical reports, patient self-reports, and interviews with the family members of 36 patients, who were randomly assigned to family or individual management, demonstrated a consistent superiority for family management. The advantages for the family approach were sustained over a two-year period. The potential mechanisms through which the family approach may have achieved its greater efficacy are discussed from a multi-determined perspective.

Relationship between plasma, RBC, and CSF lithium concentrations in human subjects.

Simultaneous measurement of plasma, RBC, and plasma lithium concentrations took place with 17 inpatients chronically treated with lithium, at various times after the last lithium dose. RBC lithium levels were significantly higher than CSF lithium levels. Specimens drawn 10 or more hours after the last dose showed higher RBC and CSF lithium and lower plasma lithium than specimens drawn 4 or less hours after the last lithium dose. None of the lithium measurements differentiated manic-depressives from schizophrenics or schizoaffectives. Plasma, RBC, and CSF lithium all intercorrelated highly and equally.

Consecutive-night reliability of portable nocturnal penile tumescence monitor.

Consecutive-night reliability of nocturnal penile tumescence (NPT) was determined in 77 patients, including 47 normal controls (NC), 16 patients with end stage renal disease on maintenance hemodialysis (ESRD), and 14 patients with chronic illnesses but normal renal functioning (CI). A portable NPT monitor was used in a clinical research ward setting. Since there is not yet widespread agreement as to the clinically most relevant NPT response criteria, three were examined: the proportion of sleep time during which an erection of a given penile circumference change was maintained, the maximum penile circumference change obtained, and the number of erections per night of a given penile circumference change. For all three response criteria in each of the three populations the consecutive-night correlation of results was statistically significant, suggesting that portable NPT has consecutive-night reliability.

Lithium effects on normal subjects. Relationships to plasma and RBC lithium levels.

15 normal subjects took lithium carbonate for 10 days in dosage sufficient to attain plasma lithium concentrations in the range of 0.7-1.4 mEg/l. Periodic blood specimens were analyzed for both plasma and RBC lithium. Subjects completed Profile of Mood States questionnaires every other day, and listed side effects. Just prior to beginning and ending the lithium trial, 10 subjects completed three tests of psychomotor function. Results indicate that such a course of lithium in normals induces dysphoric mood change and psychomotor slowing, without significant relationship to either plasma or RBC lithium concentrations.

Relationship between plasma desipramine levels and clinical outcome for RDC major depressive inpatients

Depressed patients (N=31), who met Research Diagnostic Criteria for major affective disorder-depressed, were severely ill and maintained drug-free for a 1-week period on inpatient status. They received a fixed dose (150 mg/day) of desipramine for a 4-week period with drug plasma level determination and clinical ratings performed at fixed time intervals throughout the study. Despite these rigid criteria for entrance and clinical outcome measures, no obvious relationship between plasma desipramine level and clinical outcome was found. The clinical implications of this finding are discused.